European equities traded in the US as American depositary receipts opened the week marginally lower late Monday morning, declining 0.3% to 1,539.71 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Argenx (ARGX) and internet browser company Opera (OPRA), which rose 6.4% and 3% respectively. They were followed by medical device maker EDAP TMS (EDAP) and pharmaceutical company Novo Nordisk (NVO), which increased 2.2% and 2% respectively.
The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and semiconductor company Sequans Communications (SQNS), which dropped 3.5% and 2.9% respectively. They were followed by biotech firms BioNTech (BNTX) and Evaxion (EVAX), which were down 2.2% each.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and Biodexa Pharmaceuticals (BDRX), which advanced 5.9% and 2% respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which were up 1.4% and 1.2% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which lost 2.9% and 2.8% respectively. They were followed by pharmaceutical company GSK (GSK) and biopharmaceutical company Amarin (AMRN), which were off 0.9% each.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。